These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 746249)

  • 21. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
    Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Myelomatosis. A study of 138 patients treated with melphalan, prednisone and vincristine with particular attention to the prognostic value of a stage subdivision].
    Johnsen HE; Bergmann OJ; Boesen AM; Pedersen BB; Ellegaard J; Bastrup-Madsen P
    Ugeskr Laeger; 1989 Mar; 151(13):816-21. PubMed ID: 2718264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone.
    Baldini L; Radaelli F; Chiorboli O; Fumagalli S; Cro L; Segala M; Cesana BM; Polli EE; Maiolo AT
    Cancer; 1991 Jul; 68(1):62-7. PubMed ID: 2049754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
    San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
    J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuous low dose of melphalan and prednisone in patients with multiple myeloma of very old age or severe associated disease.
    Pulsoni A; Villivà N; Cavalieri E; Falcucci P; La Verde G; Matera R; Petrucci MT; Tosti ME; Mandelli F
    Drugs Aging; 2002; 19(12):947-53. PubMed ID: 12495369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
    Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
    Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
    Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central Sweden.
    Osterborg A; Ahre A; Björkholm M; Björeman M; Brenning G; Gahrton G; Grimfors G; Gyllenhammar H; Hast R; Johansson B
    Acta Oncol; 1990; 29(6):727-31. PubMed ID: 2223143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response rate and survival in myeloma patients receiving prednisone alone.
    McIntyre OR; Pajak TF; Kyle RA; Cornwell GG; Leone L
    Med Pediatr Oncol; 1985; 13(5):239-43. PubMed ID: 4033539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208).
    Kyle RA; Seligman BR; Wallace HJ; Silver RT; Glidewell O; Holland JF
    Cancer Chemother Rep; 1975; 59(3):557-62. PubMed ID: 1203882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alternating combination chemotherapy COP (cyclophosphamide, vincristine, prednisone) and MP (melphalan, prednisone) in multiple myeloma: a multicenter phase II study (JCOG8906). Lymphoma Study Group of the Japan Clinical Oncology Group.
    Takenaka T; Shirakawa S; Mikuni C; Sai T; Shimamoto Y; Araki K; Hirano M; Miura A; Ohno Y; Ichimaru M; Hanada S; Inaba S; Konishi H; Toki H; Tajima K; Niimi M; Fukuda H; Shimoyama M
    Jpn J Clin Oncol; 1999 Oct; 29(10):485-9. PubMed ID: 10645803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU.
    Kyle RA; Gailani S; Seligman BR; Blom J; McIntyre OR; Pajak TF; Holland JF
    Cancer Treat Rep; 1979 Aug; 63(8):1265-9. PubMed ID: 476704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment.
    Song MK; Chung JS; Shin HJ; Moon JH; Lee JJ; Yoon SS; Kim JS; Lee JO; Do YR; Lee HS; Park EK;
    Ann Hematol; 2012 Jun; 91(6):889-96. PubMed ID: 22237937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.
    Hjorth M; Hellquist L; Holmberg E; Magnusson B; Rödjer S; Westin J
    Br J Haematol; 1990 Feb; 74(2):185-91. PubMed ID: 2180471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Induction and maintenance therapy in multiple myeloma. Results of a multicenter study].
    Peest D; Deicher H
    Onkologie; 1988 Feb; 11(1):39-43. PubMed ID: 3283624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
    Mateos MV; Oriol A; Martínez-López J; Teruel AI; Bengoechea E; Palomera L; de Arriba F; Esseltine DL; Cakana A; Pei L; van de Velde H; Miguel JS
    Ann Hematol; 2016 Dec; 95(12):2033-2041. PubMed ID: 27738789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of advanced plasma cell myeloma with weekly cyclophosphamide and alternate-day prednisone.
    Brandes LJ; Israels LG
    Cancer Treat Rep; 1982 Jun; 66(6):1413-5. PubMed ID: 6177412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma.
    Sakalová A; Bock PR; Dedík L; Hanisch J; Schiess W; Gazová S; Chabronová I; Holomanova D; Mistrík M; Hrubisko M
    Cancer Chemother Pharmacol; 2001 Jul; 47 Suppl():S38-44. PubMed ID: 11561871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.